Kayne Anderson Rudnick Investment Management LLC Bio Atla, Inc. Transaction History

Kayne Anderson Rudnick Investment Management LLC

$42 Billion
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $268 - $677	-126 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $551 - $2,366	126 New	126 $1,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

Soleus Capital Management, L.P. Greenwich, CT

4.07M
Shares

$5.37 Million
1.14% of portfolio
Black Rock Inc. New York, NY

2.78M
Shares

$3.67 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.1M
Shares

$2.77 Million
0.0% of portfolio
Morgan Stanley New York, NY

1.91M
Shares

$2.52 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

1.47M
Shares

$1.95 Million
0.62% of portfolio

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $47.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kayne Anderson Rudnick Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kayne Anderson Rudnick Investment Management LLC with notifications on news.

Account